Transcriptomic Biomarker Reduces False Positive Genotoxicity Tests
An international research team has developed an in vitro transcriptomic biomarker that can predict, with up to 90% accuracy, whether a drug candidate or other chemical compound is likely to cause the type of cellular injury that can lead to cancer. The TGx-DDI biomarker comprises a panel of 64 transcribed genes that reflect cellular stress response due to DNA damage. And unlike current genotoxicity assays, which demonstrate high rates of false-positive results for cancer risk, the TGx-DDI panel can distinguish between DNA-damaging chemicals that are potentially carcinogenic, and those that may be toxic to cells at high levels, but which do not pose a cancer-causing risk in vivo . The researchers, led by Albert J. Fornace Jr. M.D., professor in the departments of biochemistry and molecular & cellular biology, oncology and radiation medicine at Georgetown University School of Medicine, report on the development and validation of the TGx-DDI ...
Original Article: Transcriptomic Biomarker Reduces False Positive Genotoxicity Tests
